Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arterial infusion chemotherapy embolization plus QL1706 for first-line pancreatic cancer liver metastases
ChiCTR2600133048Phase 4Not yet recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Sep 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of QL1706, paclitaxel, gemcitabine, pirarubicin and ethiodized oil in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoints: Progression-free survival and Objective response rate. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
QL1706paclitaxelgemcitabinepirarubicinethiodized oil
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2600133048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133048.